{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/china-gcp-2020-alignment-and-approvals”
},
“@id”: “https://www.clinicalstudies.in/china-gcp-2020-alignment-and-approvals”,
“headline”: “SOP for China GCP 2020 Alignment and Approvals”,
“name”: “SOP for China GCP 2020 Alignment and Approvals”,
“description”: “Comprehensive SOP describing procedures for aligning with China GCP 2020 and obtaining necessary NMPA approvals for clinical trials, including submission workflows, documentation, and lifecycle management.”,
“keywords”: “China GCP SOP, NMPA compliance 2020, Chinese clinical trial approval, SOP for NMPA submissions, NMPA clinical trial application SOP, Chinese regulatory submissions, NMPA ethics alignment SOP, SOP for clinical trial approvals China, NMPA GCP 2020 SOP, SOP for CTA in China, SOP for NMPA trial governance, NMPA essential documents SOP, SOP for clinical trial sponsors China, NMPA ethics committee coordination, NMPA inspection readiness SOP, SOP for regulatory compliance China, NMPA approval process SOP, Chinese GCP alignment SOP, SOP for investigator compliance NMPA, SOP for NMPA document submission, SOP for China GCP audits, SOP for ethics submissions China, NMPA SOP documentation, SOP for sponsor obligations NMPA, SOP for lifecycle events China”,
“articleSection”: “Standard Operating Procedure”,
“datePublished”: “2025-08-28”,
“dateModified”: “2025-08-28”,
“author”: { “@type”: “Organization”, “name”: “Clinicalstudies.in” },
“publisher”: {
“@type”: “Organization”,
“name”: “Clinicalstudies.in”,
“logo”: { “@type”: “ImageObject”, “url”: “https://www.clinicalstudies.in/logo.png” }
}
}

China GCP 2020 Alignment and Approvals SOP

Purpose

This SOP describes the procedures for aligning sponsor and investigator activities with the China GCP (2020) requirements and securing necessary approvals from the National Medical Products Administration (NMPA). It ensures compliance with regulatory and ethical obligations for clinical trials conducted in China.

Scope

This SOP applies to all interventional clinical trials conducted in China requiring approval or notification to the NMPA and review by Ethics Committees (ECs). It covers Clinical Trial Application (CTA) submissions, substantial amendments, safety reporting, essential document management, and inspection readiness under China GCP 2020.

Responsibilities

• Sponsor: Ensures CTAs, amendments, and lifecycle events are prepared and submitted in compliance with NMPA requirements.
• Principal Investigator (PI): Provides site-level documentation and ensures EC approval prior to trial conduct.
• Regulatory Affairs (RA): Manages interactions with NMPA and ensures acknowledgment and approval documents are archived.
• Clinical Project Manager (CPM): Tracks timelines, coordinates submissions, and maintains regulatory compliance logs.
• Quality Assurance (QA): Conducts audits of NMPA submission packages and verifies alignment with GCP 2020.

Accountability

The Sponsor’s Head of Clinical Research holds accountability for ensuring organizational compliance with China GCP 2020. The PI is accountable for ensuring site-level adherence to EC and NMPA requirements.

Procedure

1. Preparation of Clinical Trial Application (CTA)

1. Compile dossier including protocol, Investigator’s Brochure (IB), informed consent forms (ICFs), investigational product (IP) details, and investigator qualifications.
2. Ensure documents are translated into Chinese and verified for accuracy.
3. Maintain CTA Submission Log in TMF.

2. Submission to NMPA

1. Submit CTA electronically via NMPA submission portal.
2. Record acknowledgment receipt, reference number, and submission date.
3. Maintain all submission-related correspondence in TMF.

3. Ethics Committee Coordination

1. Ensure EC approval is obtained prior to trial initiation at each site.
2. Submit bilingual ICFs and patient-facing materials for EC review.
3. Record EC approval letters in ISF and TMF.

4. Amendments and Notifications

1. Classify amendments as substantial or administrative.
2. Submit substantial amendments to NMPA and EC prior to implementation.
3. Record approvals in Amendment Log.

5. Safety Reporting

1. Submit SAEs and SUSARs in compliance with NMPA timelines.
2. Prepare Development Safety Update Reports (DSURs) annually.

6. Inspection Readiness

1. Maintain essential documents in TMF and ISF in line with GCP 2020.
2. Prepare sites and sponsors for NMPA inspections.

7. Archiving

1. Archive CTA submissions, approvals, amendments, and safety reports for 15 years or per NMPA rules.

Abbreviations

• NMPA: National Medical Products Administration
• CTA: Clinical Trial Application
• EC: Ethics Committee
• PI: Principal Investigator
• IB: Investigator’s Brochure
• ICF: Informed Consent Form
• IP: Investigational Product
• QA: Quality Assurance
• TMF: Trial Master File
• ISF: Investigator Site File

Documents

1. CTA Submission Log (Annexure-1)
2. Amendment Log (Annexure-2)
3. EC Approval Tracker (Annexure-3)

References

• National Medical Products Administration (NMPA)
• ICH E6(R2) Good Clinical Practice
• ICH Efficacy Guidelines
• China Clinical Trial Registry

Version: 1.0

Approval

Annexures

Annexure-1: CTA Submission Log

Annexure-2: Amendment Log

Annexure-3: EC Approval Tracker

Revision History

For more SOPs visit: Pharma SOP.